DK2951203T3 - Heterodimere proteiner - Google Patents
Heterodimere proteiner Download PDFInfo
- Publication number
- DK2951203T3 DK2951203T3 DK14733393.4T DK14733393T DK2951203T3 DK 2951203 T3 DK2951203 T3 DK 2951203T3 DK 14733393 T DK14733393 T DK 14733393T DK 2951203 T3 DK2951203 T3 DK 2951203T3
- Authority
- DK
- Denmark
- Prior art keywords
- heterodimering
- proteins
- heterodimering proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361794896P | 2013-03-15 | 2013-03-15 | |
US201361818344P | 2013-05-01 | 2013-05-01 | |
US201361818153P | 2013-05-01 | 2013-05-01 | |
US201361818401P | 2013-05-01 | 2013-05-01 | |
US201361913832P | 2013-12-09 | 2013-12-09 | |
US201361913879P | 2013-12-09 | 2013-12-09 | |
US201361913870P | 2013-12-09 | 2013-12-09 | |
US14/155,334 US10738132B2 (en) | 2013-01-14 | 2014-01-14 | Heterodimeric proteins |
PCT/US2014/011549 WO2014110601A1 (en) | 2013-01-14 | 2014-01-14 | Novel heterodimeric proteins |
US201461938095P | 2014-02-10 | 2014-02-10 | |
US14/205,248 US9650446B2 (en) | 2013-01-14 | 2014-03-11 | Heterodimeric proteins |
US14/207,489 US10131710B2 (en) | 2013-01-14 | 2014-03-12 | Optimized antibody variable regions |
PCT/US2014/030634 WO2014145806A2 (en) | 2013-03-15 | 2014-03-17 | Heterodimeric proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2951203T3 true DK2951203T3 (da) | 2019-08-12 |
Family
ID=54065613
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14733393.4T DK2951203T3 (da) | 2013-03-15 | 2014-03-17 | Heterodimere proteiner |
DK19175124.7T DK3587448T3 (da) | 2013-03-15 | 2014-03-17 | Heterodimere proteiner |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK19175124.7T DK3587448T3 (da) | 2013-03-15 | 2014-03-17 | Heterodimere proteiner |
Country Status (16)
Country | Link |
---|---|
EP (3) | EP2951203B1 (da) |
JP (4) | JP6594855B2 (da) |
KR (3) | KR102211176B1 (da) |
CN (2) | CN111138543B (da) |
AU (4) | AU2014232501C1 (da) |
CA (1) | CA2902739C (da) |
CY (1) | CY1122053T1 (da) |
DK (2) | DK2951203T3 (da) |
ES (2) | ES2885696T3 (da) |
HR (1) | HRP20191470T1 (da) |
HU (1) | HUE044689T2 (da) |
IL (2) | IL241431B (da) |
LT (1) | LT2951203T (da) |
PL (1) | PL3587448T3 (da) |
SI (1) | SI2951203T1 (da) |
WO (1) | WO2014145806A2 (da) |
Families Citing this family (173)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2006381B1 (en) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
ES2563483T3 (es) | 2008-04-11 | 2016-03-15 | Chugai Seiyaku Kabushiki Kaisha | Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno |
EP2598530A2 (en) | 2010-07-29 | 2013-06-05 | Xencor, Inc. | Antibodies with modified isoelectric points |
US20140234340A1 (en) | 2010-11-30 | 2014-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
CA2882272C (en) | 2012-08-24 | 2023-08-29 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc region variant |
WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
CN105051069B (zh) | 2013-01-14 | 2019-12-10 | Xencor股份有限公司 | 新型异二聚体蛋白 |
CA2897987A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
JP6594855B2 (ja) | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
AU2014232416B2 (en) | 2013-03-15 | 2017-09-28 | Xencor, Inc. | Modulation of T Cells with Bispecific Antibodies and FC Fusions |
US11634502B2 (en) | 2013-03-15 | 2023-04-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
US20160031985A1 (en) * | 2013-03-15 | 2016-02-04 | Katherine S. Bowdish | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use |
EP2982689B1 (en) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
CA2922979A1 (en) | 2013-09-03 | 2015-03-12 | Novimmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
EP3066133A1 (en) * | 2013-11-04 | 2016-09-14 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
EA201691925A1 (ru) * | 2014-03-28 | 2017-06-30 | Ксенкор, Инк. | Биспецифические антитела, которые связываются с cd38 и cd3 |
AP2017009823A0 (en) | 2014-09-26 | 2017-03-31 | Macrogenics Inc | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof |
EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
CN107108745B (zh) | 2014-11-19 | 2021-01-12 | 基因泰克公司 | 抗bace1的抗体和其用于神经疾病免疫疗法的用途 |
US20160176969A1 (en) * | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
BR112017011092A2 (pt) * | 2014-11-26 | 2017-12-26 | Xencor Inc | anticorpos heterodiméricos que ligam cd3 e antígenos de tumor |
PE20171103A1 (es) | 2014-11-26 | 2017-08-07 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38 |
SG11201700841QA (en) | 2014-12-19 | 2017-03-30 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
WO2016105450A2 (en) * | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用 |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
JP6694446B2 (ja) * | 2015-05-08 | 2020-05-13 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3および腫瘍抗原に結合するヘテロ二量体抗体 |
US10227410B2 (en) | 2015-12-07 | 2019-03-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
CA2997406C (en) | 2015-12-09 | 2024-05-28 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
EP3464370A1 (en) | 2016-06-01 | 2019-04-10 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
US20170349660A1 (en) | 2016-06-01 | 2017-12-07 | Xencor. Inc. | Bispecific antibodies that bind cd123 and cd3 |
CA3059010A1 (en) | 2016-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
MX2018015592A (es) | 2016-06-14 | 2019-04-24 | Xencor Inc | Anticuerpos inhibidores de puntos de control biespecificos. |
JP7021127B2 (ja) | 2016-06-28 | 2022-02-16 | ゼンコア インコーポレイテッド | ソマトスタチン受容体2に結合するヘテロ二量体抗体 |
CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
AU2017321625A1 (en) * | 2016-08-30 | 2019-04-04 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
MX2019004327A (es) * | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
CN116970061A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
WO2018129522A1 (en) | 2017-01-09 | 2018-07-12 | Torch Therapeutics | Conditionally effective bispecific therapeutics |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
CN110573530A (zh) * | 2017-02-20 | 2019-12-13 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的蛋白 |
EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
US11866507B2 (en) | 2017-04-11 | 2024-01-09 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
CN111344303A (zh) | 2017-06-01 | 2020-06-26 | Xencor股份有限公司 | 结合cd123和cd3的双特异性抗体 |
WO2018223004A1 (en) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
CA3176049A1 (en) * | 2017-08-16 | 2019-02-21 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1 |
BR112020003654A2 (pt) * | 2017-08-23 | 2020-11-17 | Dragonfly Therapeutics, Inc. | proteínas de ligação ao nkg2d, cd16 e a um antígeno associado a tumor |
EP3688036A4 (en) * | 2017-09-25 | 2021-06-23 | Dingfu Biotarget Co., Ltd | PROTEINOUS HETERODIMER AND USE OF IT |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
JP2021506291A (ja) | 2017-12-19 | 2021-02-22 | ゼンコア インコーポレイテッド | 改変されたil−2 fc融合タンパク質 |
MX2020008219A (es) | 2018-02-08 | 2020-10-22 | Amgen Inc | Formulacion farmaceutica de ph bajo. |
CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
SG11202007945UA (en) * | 2018-02-20 | 2020-09-29 | Dragonfly Therapeutics Inc | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
CA3093729A1 (en) | 2018-03-15 | 2019-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
JP7427605B2 (ja) * | 2018-04-05 | 2024-02-05 | ノバルティス アーゲー | 癌に対する三重特異性結合分子及びその使用 |
SG11202009804RA (en) * | 2018-04-11 | 2020-11-27 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
CA3097649A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
CA3097625A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
CA3097741A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
US20210230281A1 (en) | 2018-04-27 | 2021-07-29 | Novartis Ag | Dosing of a bispecific antibody that bind cd123 and cd3 |
EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
JP2021525769A (ja) | 2018-06-01 | 2021-09-27 | ノバルティス アーゲー | Cd123及びcd3に結合する二重特異性抗体の投与 |
CU20200089A7 (es) | 2018-06-01 | 2021-07-02 | Novartis Ag | Moléculas de unión contra bcma |
EP3802605A1 (en) | 2018-06-01 | 2021-04-14 | Compugen Ltd. | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
TW202019965A (zh) | 2018-07-16 | 2020-06-01 | 美商安進公司 | 治療多發性骨髓瘤之方法 |
EP3827019A1 (en) | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
EP3861016A2 (en) | 2018-10-03 | 2021-08-11 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
CA3114693A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
JP2022504822A (ja) | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | Dll3シングルドメイン抗体およびその治療用組成物 |
CA3115082A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
CA3116188A1 (en) | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof |
AU2019389354A1 (en) | 2018-11-30 | 2021-07-15 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment and pharmaceutical use thereof |
TW202033218A (zh) * | 2018-12-07 | 2020-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 多特異性蛋白分子 |
EP3897853A1 (en) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
US12006345B2 (en) | 2019-02-21 | 2024-06-11 | Xencor, Inc. | Untargeted and targeted IL-10 Fc-fusion proteins |
CN114173875A (zh) | 2019-03-01 | 2022-03-11 | Xencor股份有限公司 | 结合enpp3和cd3的异二聚抗体 |
EP3947459A1 (en) | 2019-03-29 | 2022-02-09 | Xencor, Inc. | Dosing of a bispecific antibody that binds pd1 and ctla4 |
WO2020226502A2 (en) * | 2019-05-09 | 2020-11-12 | Merus N.V. | Variant domains for multimerizing proteins and separation thereof |
CN114080397A (zh) | 2019-05-17 | 2022-02-22 | Xencor股份有限公司 | Il-7-fc融合蛋白 |
MX2021014189A (es) | 2019-05-20 | 2022-01-06 | Cytune Pharma | Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas. |
JOP20210309A1 (ar) | 2019-05-21 | 2023-01-30 | Novartis Ag | جزيئات ربط بـ cd19 واستخدامتها |
EP3972993A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Variant cd58 domains and uses thereof |
AU2020279224A1 (en) | 2019-05-21 | 2021-12-16 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
MX2021014476A (es) * | 2019-05-29 | 2022-02-11 | Cue Biopharma Inc | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. |
JP2022534513A (ja) * | 2019-05-31 | 2022-08-01 | ザ・ジョンズ・ホプキンス・ユニバーシティー | がん細胞遊走を阻害するためのIL-6Rα/IL-8R二重特異性結合剤 |
US20220235133A1 (en) * | 2019-06-24 | 2022-07-28 | Nanjing GenScript Biotech Co., Ltd. | Monoclonal antibody-cytokine fusion protein dimer and application thereof |
WO2021026387A2 (en) | 2019-08-06 | 2021-02-11 | Xencor, Inc. | HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES |
CN115916233A (zh) | 2019-10-03 | 2023-04-04 | Xencor股份有限公司 | 靶向IL-12异源二聚体Fc融合蛋白 |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Ose Immunotherapeutics | Bifunctional molecules comprising an IL-7 variant |
CN115279796A (zh) * | 2020-01-23 | 2022-11-01 | 天演药业(瑞士)公司 | 具有Fc突变的异二聚蛋白质 |
WO2021155071A1 (en) | 2020-01-29 | 2021-08-05 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
TW202146452A (zh) | 2020-02-28 | 2021-12-16 | 瑞士商諾華公司 | 結合cd123和cd3之雙特異性抗體的給藥 |
US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
EP4126241A1 (en) | 2020-03-27 | 2023-02-08 | Novartis AG | Bispecific combination therapy for treating proliferative diseases and autoimmune disorders |
CA3182697A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
US20220106403A1 (en) | 2020-05-14 | 2022-04-07 | Xencor, Inc. | Heterodimeric antibodies that bind msln and cd3 |
AU2021302126A1 (en) * | 2020-06-30 | 2023-02-09 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
KR20220014531A (ko) * | 2020-07-29 | 2022-02-07 | (주)메디톡스 | 헤테로이량체 Fc 융합 단백질, 및 관련 조성물, 용도 및 방법 |
CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
WO2022061240A1 (en) * | 2020-09-21 | 2022-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Heteromultimeric proteins for reducing ige-dependent allergic effector cell activation |
AR123767A1 (es) | 2020-10-13 | 2023-01-11 | Janssen Biotech Inc | Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii |
US20220135684A1 (en) | 2020-10-14 | 2022-05-05 | Xencor, Inc. | Bispecific antibodies that bind pd-l1 and cd28 |
WO2022087418A1 (en) | 2020-10-23 | 2022-04-28 | Xencor, Inc. | Anti-cd20 antibodies and therapeutic uses thereof |
AU2021367887A1 (en) | 2020-10-26 | 2023-06-01 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
JP2023550880A (ja) | 2020-10-26 | 2023-12-06 | サイチューン ファーマ | 非黒色腫皮膚癌を治療するためのIL-2/IL-15Rβγアゴニスト |
IL302569A (en) | 2020-11-06 | 2023-07-01 | Novartis Ag | CD19 binding molecules and their uses |
CA3199839A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
US20220144956A1 (en) | 2020-11-06 | 2022-05-12 | Xencor, Inc. | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII |
AU2021402065A1 (en) | 2020-12-17 | 2023-06-29 | Ose Immunotherapeutics | Bifunctional anti-pd1/il-7 molecules |
WO2022140701A1 (en) | 2020-12-24 | 2022-06-30 | Xencor, Inc. | Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and icos antigen binding domains |
CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
JP2024515263A (ja) | 2021-04-09 | 2024-04-08 | オーエスイー・イミュノセラピューティクス | 改善された特性を有する二機能性分子のための新規足場構造 |
US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
JP2024514802A (ja) | 2021-04-22 | 2024-04-03 | 広東菲鵬制▲薬▼股▲ふん▼有限公司 | 二重特異性多機能性融合ポリペプチド |
AU2021443318A1 (en) | 2021-04-30 | 2023-09-07 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
CA3217803A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
WO2022266219A1 (en) | 2021-06-15 | 2022-12-22 | Xencor, Inc. | Heterodimeric antibodies that bind claudin18.2 and cd3 |
KR20240023123A (ko) | 2021-06-22 | 2024-02-20 | 노파르티스 아게 | 화농성 한선염의 치료에 사용하기 위한 이중특이적 항체 |
AU2022296794A1 (en) * | 2021-06-23 | 2023-12-14 | Cytune Pharma | Interleukin-15 based immunocytokines |
EP4362984A1 (en) | 2021-07-02 | 2024-05-08 | Yale University | Compositions and methods for treating cancers |
US20230146665A1 (en) | 2021-07-27 | 2023-05-11 | Xencor, Inc. | Il-18-fc fusion proteins |
CA3225815A1 (en) | 2021-08-13 | 2023-02-16 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
WO2023028162A1 (en) * | 2021-08-25 | 2023-03-02 | Biograph 55, Inc. | Antibodies targeting immunosuppressive b cells |
CA3229824A1 (en) * | 2021-08-25 | 2023-03-02 | Leonard Presta | Methods of treating cancers associated with immunosuppressive b cells |
WO2023034864A1 (en) | 2021-08-31 | 2023-03-09 | Yale University | Compositions and methods for treating cancers |
CN118043356A (zh) | 2021-09-27 | 2024-05-14 | Xencor股份有限公司 | B细胞成熟抗原(bcma)结合结构域组合物 |
WO2023081915A1 (en) | 2021-11-08 | 2023-05-11 | Xencor, Inc. | Il-8 as a predictive biomarker and methods of use thereof for the treatment of cancer |
CA3240046A1 (en) | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Dual mhc-targeting t cell engager |
US20230265218A1 (en) | 2022-02-23 | 2023-08-24 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023196905A1 (en) | 2022-04-07 | 2023-10-12 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
US20230383012A1 (en) | 2022-04-13 | 2023-11-30 | Xencor, Inc. | Antibodies that bind pd-l1, pd-l2, and/or cd28 |
TW202400658A (zh) | 2022-04-26 | 2024-01-01 | 瑞士商諾華公司 | 靶向il—13和il—18的多特異性抗體 |
WO2024003376A1 (en) | 2022-07-01 | 2024-01-04 | Alk-Abelló A/S | Displacers of ige-fceri |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
WO2024056758A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
US20240166705A1 (en) | 2022-11-07 | 2024-05-23 | Xencor, Inc. | Il18-fc fusion proteins |
WO2024102645A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Combination treatment with a bispecific antibody that binds ctla4 and pd1 for prostate cancer |
WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
JPH0684377B1 (da) | 1986-04-17 | 1994-10-26 | Kyowa Hakko Kogyo Kk | |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質dc113 |
JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Dc―88a誘導体 |
US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1991017158A1 (en) | 1990-05-07 | 1991-11-14 | Scripps Clinic And Research Foundation | Intermediates in the formation of the calicheamicin and esperamicin oligosaccharides |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
AU689131B2 (en) | 1993-10-01 | 1998-03-26 | Teikoku Hormone Mfg. Co., Ltd. | Novel peptide derivative |
PT705833E (pt) | 1994-04-22 | 2004-11-30 | Kyowa Hakko Kogyo Kk | Derivado de dc-89 |
JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5550246A (en) | 1994-09-07 | 1996-08-27 | The Scripps Research Institute | Calicheamicin mimics |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
WO1997023243A1 (en) | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
WO1998048032A2 (en) | 1997-04-21 | 1998-10-29 | Donlar Corporation | POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
EP2314686B2 (en) | 2000-10-06 | 2023-06-21 | Kyowa Kirin Co., Ltd. | Cells producing antibody compositions |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7087600B2 (en) | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
AU2003248370A1 (en) | 2002-02-27 | 2003-09-09 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
DE10246870B3 (de) | 2002-10-08 | 2004-04-29 | Renk Aktiengesellschaft | Elektro-Hydrodynamische Überlagerungslenkung |
US7705045B2 (en) | 2002-11-14 | 2010-04-27 | Syntarga, B.V. | Prodrugs built as multiple self-elimination-release spacers |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
ES2559670T3 (es) | 2003-05-20 | 2016-02-15 | Immunogen, Inc. | Agentes citotóxicos mejorados que comprenden nuevos maitansinoides |
FR2855046B1 (fr) | 2003-05-23 | 2005-07-22 | Oreal | Composition tinctoriale comprenant au moins un precurseur de colorant et un coplolymere sequence amphiphile |
US7888134B2 (en) * | 2003-06-05 | 2011-02-15 | Oakland University | Immunosensors: scFv-linker design for surface immobilization |
ES2831379T3 (es) | 2003-10-09 | 2021-06-08 | Ambrx Inc | Derivados poliméricos para la modificación selectiva de proteínas |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
NZ548256A (en) | 2004-02-02 | 2010-02-26 | Ambrx Inc | Modified human four helical bundle polypeptides and their uses |
NZ550934A (en) | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
WO2006131013A2 (en) | 2005-06-07 | 2006-12-14 | Esbatech Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
US9017992B2 (en) * | 2005-07-01 | 2015-04-28 | Dako Denmark A/S | In situ hybridization detection method |
JP2009509918A (ja) | 2005-08-05 | 2009-03-12 | シンタルガ・ビーブイ | トリアゾール含有放出可能なリンカー、これらの共役体、および製造方法 |
EA014025B1 (ru) | 2005-09-12 | 2010-08-30 | Новиммун С.А. | Композиции антитела против cd3 |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
CN101415679A (zh) | 2006-02-02 | 2009-04-22 | 辛塔佳有限公司 | 水溶性cc-1065类似物及其缀合物 |
EP4218801A3 (en) * | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
CN101460622A (zh) * | 2006-03-31 | 2009-06-17 | 中外制药株式会社 | 用于纯化双特异性抗体的抗体修饰方法 |
AU2007357156B2 (en) | 2007-08-01 | 2013-01-10 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
JP6157046B2 (ja) * | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法 |
EP2344478B1 (en) | 2008-11-03 | 2017-09-27 | Syntarga B.V. | Cc-1065 analogs and their conjugates |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US10817851B2 (en) | 2009-12-23 | 2020-10-27 | Aristocrat Technologies Australia Pty Limited | System and method for cashless gaming |
EP2522724B1 (en) * | 2009-12-25 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide modification method for purifying polypeptide multimers |
WO2011143545A1 (en) * | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
JP6167040B2 (ja) * | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
DK2637670T4 (da) | 2010-11-10 | 2024-03-25 | Amgen Res Munich Gmbh | Forebyggelse af uønskede hændelser forårsaget af specifikke cd3-bindingsdomæner |
CN108285488B (zh) * | 2011-03-25 | 2023-01-24 | 伊克诺斯科学公司 | 异二聚体免疫球蛋白 |
CN103648529A (zh) | 2011-04-28 | 2014-03-19 | 安进研发(慕尼黑)股份有限公司 | 用于给处于潜在不良反应的风险的患者施用CD19xCD3双特异性抗体的给药方案 |
US9181334B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
EP2744931B1 (en) | 2011-08-18 | 2018-05-02 | Affinity Biosciences Pty Ltd | Soluble polypeptides |
WO2013033008A2 (en) * | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
DK2766392T3 (da) | 2011-10-10 | 2019-10-07 | Xencor Inc | Fremgangsmåde til oprensning af antistoffer |
CN105051069B (zh) | 2013-01-14 | 2019-12-10 | Xencor股份有限公司 | 新型异二聚体蛋白 |
JP6594855B2 (ja) | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
AU2014232416B2 (en) * | 2013-03-15 | 2017-09-28 | Xencor, Inc. | Modulation of T Cells with Bispecific Antibodies and FC Fusions |
US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2014
- 2014-03-17 JP JP2016503432A patent/JP6594855B2/ja active Active
- 2014-03-17 AU AU2014232501A patent/AU2014232501C1/en active Active
- 2014-03-17 ES ES19175124T patent/ES2885696T3/es active Active
- 2014-03-17 PL PL19175124T patent/PL3587448T3/pl unknown
- 2014-03-17 CA CA2902739A patent/CA2902739C/en active Active
- 2014-03-17 LT LTEP14733393.4T patent/LT2951203T/lt unknown
- 2014-03-17 KR KR1020157023088A patent/KR102211176B1/ko active IP Right Grant
- 2014-03-17 SI SI201431314T patent/SI2951203T1/sl unknown
- 2014-03-17 WO PCT/US2014/030634 patent/WO2014145806A2/en active Application Filing
- 2014-03-17 EP EP14733393.4A patent/EP2951203B1/en active Active
- 2014-03-17 DK DK14733393.4T patent/DK2951203T3/da active
- 2014-03-17 CN CN201910997432.7A patent/CN111138543B/zh active Active
- 2014-03-17 KR KR1020227021238A patent/KR102561553B1/ko active IP Right Grant
- 2014-03-17 DK DK19175124.7T patent/DK3587448T3/da active
- 2014-03-17 CN CN201480014664.1A patent/CN105377889B/zh active Active
- 2014-03-17 EP EP19175124.7A patent/EP3587448B1/en active Active
- 2014-03-17 ES ES14733393T patent/ES2743216T3/es active Active
- 2014-03-17 KR KR1020217002769A patent/KR102413494B1/ko active IP Right Grant
- 2014-03-17 EP EP21173787.9A patent/EP3936521A1/en active Pending
- 2014-03-17 HU HUE14733393 patent/HUE044689T2/hu unknown
-
2015
- 2015-09-10 IL IL241431A patent/IL241431B/en unknown
-
2019
- 2019-06-06 AU AU2019203977A patent/AU2019203977B2/en active Active
- 2019-08-06 CY CY20191100832T patent/CY1122053T1/el unknown
- 2019-08-14 HR HRP20191470TT patent/HRP20191470T1/hr unknown
- 2019-09-25 JP JP2019174528A patent/JP7012052B2/ja active Active
-
2020
- 2020-12-24 AU AU2020294326A patent/AU2020294326A1/en not_active Abandoned
-
2021
- 2021-06-22 IL IL284301A patent/IL284301A/en unknown
-
2022
- 2022-01-17 JP JP2022004795A patent/JP7323659B2/ja active Active
-
2023
- 2023-07-27 JP JP2023122227A patent/JP2023156361A/ja active Pending
-
2024
- 2024-06-21 AU AU2024204284A patent/AU2024204284A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301171I1 (nl) | Tigolaner | |
DK2951203T3 (da) | Heterodimere proteiner | |
DK3342773T3 (da) | Syk-hæmmere | |
DK2970464T3 (da) | Anti-lag-3-bindende proteiner | |
DK3613453T3 (da) | Fordamper | |
DK3041857T3 (da) | Protein a-kromatografi | |
DK3077047T3 (da) | Aramcholsalte | |
DK3060460T3 (da) | Saddel | |
DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
DK2956698T5 (da) | Bindestrimler | |
DK3052081T3 (da) | Pastil | |
DK2946640T3 (da) | Langmuir-probe | |
DK3071227T3 (da) | Fiskevaccine | |
DE102013106534B8 (de) | Chromatographiepipettenspitze | |
DE112014001252A5 (de) | Aufbissschiene | |
FI20135542A (fi) | Rumpusuodinlaite | |
DK3089990T3 (da) | Forbedret proteinekspression | |
DK2981168T3 (da) | Laminitiskile | |
DK3089991T3 (da) | Forbedret proteinekspression | |
DK3086679T3 (da) | Sportssko | |
FR3014440B1 (fr) | Polypeptides entomotoxiques | |
FI10138U1 (fi) | Kelkkateltta | |
ES1078715Y (es) | Mosquitera | |
DE112014005422A5 (de) | Friktionsfalschdrallaggregat | |
BR112016000501A2 (pt) | Nalador |